Ron Andrews, Clarient's President and Chief Executive Officer, stated, "The completion of this important milestone on schedule is a testimony to the hard work and dedication of our development team. Clarient undertook a challenging development timeline to deliver this evolution of our cellular imaging product line in under a year. We knew when we committed to this condensed schedule that it would really test the new project management culture we have instilled at Clarient. While we still have a few final development activities left before full market launch, these shipments validate our ability to deliver complex projects on time and within budget. With the vast majority of the development now behind us, we look forward to the commencement of the commercial launch phase with Dako, our distribution partner."
About Clarient Inc.
Clarient (www.clarientinc.com) combines innovative technologies with world class expertise to assess and characterize cancer. Clarient's mission is to provide technologies, services and the critical information to improve the quality and reduce the cost of patient care as well as accelerating the drug development process. The Company's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies.
The company was formed in 1996 to develop and market the ACIS® Automated Cellular Imaging System(TM), an important advancement in slide-based testing. The rise of individualized medicine as the new direction in oncology led the company in 2004 to expand its business model to provide the full range of leading diagnostic technologies such as flow cytometry and molecular testing in-house, creating a state-of-the-art commercial cancer laboratory and providing the most advanced oncology testing and drug development services available. For more information, visit www.clarientinc.com.
About Safeguard
Safeguard Scientifics, Inc. (NYSE: SFE - News) builds value in high-growth, revenue-stage information technology and life sciences businesses. Safeguard provides growth capital as well as a range of strategic, operating and management resources to our partner companies. The company participates in expansion financings, corporate spin-outs, management buyouts, recapitalizations, industry consolidations and early-stage financings. For more information about Safeguard, please visit www.safeguard.com.
The company does not assume any obligation to update any forward-looking statements or other information contained in this document.
Contact: Charlene Lu Clarient, Inc. (203) 682 8268 charlene.lu@icrinc.com
Source: Clarient, Inc.
